作者
Robert D. Morgan,Andrew R. Clamp,Bethany M. Barnes,Kirsten M. Timms,Hélene Schlecht,Laura Yarram-Smith,Yvonne Wallis,Mikel Valganon-Petrizan,Suzanne MacMahon,Rhian White,Siân Morgan,Sarah McKenna,Emma Hudson,Laura A. Tookman,Angela George,Ranjit Manchanda,Sudha Sundar,Shibani Nicum,James D. Brenton,Rebecca Kristeleit,Susana Banerjee,Iain A. McNeish,Jonathan A. Ledermann,Stephen S. Taylor,D. Gareth Evans,Gordon C. Jayson
摘要
Olaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer with a deficiency in homologous recombination. We report data from the first year of routine homologous recombination deficiency testing in the National Health Service (NHS) in England, Wales, and Northern Ireland between April 2021 and April 2022.